Recent Quotes (30 days)

You have no recent quotes
chg | %

Arbutus Biopharma Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
22.97
Mar 3 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Nov 1, 2017
Q3 2017 Arbutus Biopharma Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 27, 2017
Arbutus Biopharma Corp at Cantor Fitzgerald Global Healthcare Conference - 8:00AM EDT - Add to calendar
Sep 12, 2017
Arbutus Biopharma Corp to Discuss Developments of LNP Delivery for mRNA-based Therapeutics - Webinar
Aug 16, 2017
Arbutus Biopharma Corp at Wedbush PacGrow Healthcare Conference
Aug 3, 2017
Q2 2017 Arbutus Biopharma Corp Earnings Call - Webcast
Aug 3, 2017
Q2 2017 Arbutus Biopharma Corp Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Pky
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.